CY1118462T1 - Μονοκλωνικο αντισωμα κατα της πρωτεϊνης συνδεσης οστεοπροτεγερινης - Google Patents

Μονοκλωνικο αντισωμα κατα της πρωτεϊνης συνδεσης οστεοπροτεγερινης

Info

Publication number
CY1118462T1
CY1118462T1 CY20171100035T CY171100035T CY1118462T1 CY 1118462 T1 CY1118462 T1 CY 1118462T1 CY 20171100035 T CY20171100035 T CY 20171100035T CY 171100035 T CY171100035 T CY 171100035T CY 1118462 T1 CY1118462 T1 CY 1118462T1
Authority
CY
Cyprus
Prior art keywords
osteoprotein
monoclonal antibody
antibody against
protein connection
opgbp
Prior art date
Application number
CY20171100035T
Other languages
English (en)
Inventor
Rajendra V Deshpande
Anna Hitz
William J Boyle
John K Sullivan
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01911158.2A external-priority patent/EP1257648B2/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1118462T1 publication Critical patent/CY1118462T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Με την εφεύρεση παρέχονται επιλεκτικά μέσα σύνδεσης της πρωτεΐνης σύνδεσης οστεοπροτεγερίνης (OPGbp). Πιο συγκεκριμένα, η εφεύρεση παρέχει αντισώματα και περιοχές σύνδεσης αντιγόνου που συνδέονται επιλεκτικώς με OPGbp και μπορούν να χρησιμοποιηθούν για την πρόληψη ή θεραπεία παθήσεων που συνδέονται με την απώλεια οστικής μάζας. Παρέχονται επίσης τα μόρια νουκλεϊκού οξέος που κωδικοποιούν τα εν λόγω αντισώματα και περιοχές που συνδέουν αντιγόνο και φορείς έκφρασης και κύτταρα ξενιστές για την παραγωγή των ιδίων.
CY20171100035T 2000-02-23 2017-01-11 Μονοκλωνικο αντισωμα κατα της πρωτεϊνης συνδεσης οστεοπροτεγερινης CY1118462T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51113900A 2000-02-23 2000-02-23
US09/791,153 US20030103978A1 (en) 2000-02-23 2001-02-22 Selective binding agents of osteoprotegerin binding protein
EP01911158.2A EP1257648B2 (en) 2000-02-23 2001-02-23 Antagonistic selective binding agents of osteoprotegerin binding protein
EP08010991.1A EP2105449B1 (en) 2000-02-23 2001-02-23 Antagonistic selective binding agents of osteoprotegerin binding protein

Publications (1)

Publication Number Publication Date
CY1118462T1 true CY1118462T1 (el) 2017-07-12

Family

ID=24033610

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20081100919T CY1108297T1 (el) 2000-02-23 2008-08-26 Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
CY20141100821T CY1115634T1 (el) 2000-02-23 2014-10-10 Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
CY20171100035T CY1118462T1 (el) 2000-02-23 2017-01-11 Μονοκλωνικο αντισωμα κατα της πρωτεϊνης συνδεσης οστεοπροτεγερινης
CY20191100907T CY1121931T1 (el) 2000-02-23 2019-08-26 Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
CY20191101324T CY1122686T1 (el) 2000-02-23 2019-12-17 Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20081100919T CY1108297T1 (el) 2000-02-23 2008-08-26 Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
CY20141100821T CY1115634T1 (el) 2000-02-23 2014-10-10 Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20191100907T CY1121931T1 (el) 2000-02-23 2019-08-26 Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
CY20191101324T CY1122686T1 (el) 2000-02-23 2019-12-17 Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης

Country Status (13)

Country Link
US (2) US20030103978A1 (el)
EP (5) EP2330197B1 (el)
JP (7) JP5279425B2 (el)
AT (1) ATE398676T2 (el)
CY (5) CY1108297T1 (el)
DK (4) DK2330197T3 (el)
ES (5) ES2612124T3 (el)
HK (1) HK1158696A1 (el)
LT (1) LT2105449T (el)
MX (2) MX363225B (el)
PT (5) PT2105449T (el)
SI (3) SI2105449T1 (el)
TW (1) TWI322182B (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
KR100496063B1 (ko) * 1997-04-15 2005-06-21 산쿄 가부시키가이샤 신규단백질 및 그 제조방법
EP1717315A3 (en) * 1997-04-16 2007-06-20 Amgen Inc. Osteoprotegerin binding proteins and receptors
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
DK2009025T3 (da) 1998-05-14 2011-11-14 Immunex Corp Fremgangsmåde til hæmning af osteoklast-aktivitet
WO2003086289A2 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7052694B2 (en) * 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US7491803B2 (en) * 2003-04-30 2009-02-17 Japan Science & Technology Agency Human anti-human interleukin-18 antibody, fragment thereof and method for using same
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
WO2006017759A2 (en) * 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
PE20070684A1 (es) * 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
DK2240203T3 (da) 2008-02-05 2014-05-05 Pfizer Alfa5-beta1-antistoffer og deres anvendelser
EP2328615A2 (en) * 2008-08-20 2011-06-08 Centocor Ortho Biotech Inc. Engineered anti-il-13 antibodies, compositions, methods and uses
KR101151805B1 (ko) 2008-10-20 2012-06-01 광주과학기술원 바이포달 펩타이드 바인더
JP5677454B2 (ja) * 2009-12-11 2015-02-25 グワンジュ・インスティテュート・オブ・サイエンス・アンド・テクノロジー 細胞内ターゲット結合用二座ペプチドバインダー
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
CA2862745A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9753030B2 (en) * 2013-03-06 2017-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Degradable carbon nanotube-containing biosensors and methods for target clinical marker detection
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
CN113527512A (zh) 2013-07-31 2021-10-22 美国安进公司 生长分化因子15(gdf-15)构建体
CA2923145A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
EP3467501B1 (en) 2014-05-16 2020-11-04 Amgen Inc. Assay for detecting th1 and th2 cell populations
CA2965960A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
MX2018001522A (es) * 2015-08-05 2018-03-15 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos.
CN110418846A (zh) 2017-03-14 2019-11-05 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制
BR112020019559A2 (pt) 2018-03-26 2021-01-12 Amgen Inc. Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
JOP20200258A1 (ar) 2018-04-09 2020-10-11 Amgen Inc البروتينات الاندماجية لعامل تمايز النمو 15
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
US20230416343A1 (en) * 2020-08-07 2023-12-28 Sorrento Therapeutics, Inc. Neutralizing Antibodies that Bind the SARS-COV-2 S Protein
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
JP3192651B2 (ja) 1988-05-27 2001-07-30 アムジェン，インコーポレーテッド インターロイキン―１インヒビター
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
JP3356775B2 (ja) * 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
MX9204303A (es) * 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) * 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
ATE202571T1 (de) * 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US5641747A (en) * 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
ATE503013T1 (de) * 1995-06-29 2011-04-15 Immunex Corp Cytokin welches apoptose induziert
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US5981220A (en) * 1996-03-27 1999-11-09 Human Genome Sciences, Inc. Epidermal differentiation factor
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
DK1114864T4 (da) * 1996-12-13 2012-09-03 Schering Corp Pattedyrcelleoverfladeantigener samt tilhørende reagenser
AU5901598A (en) * 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
ATE497001T1 (de) * 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
KR100496063B1 (ko) * 1997-04-15 2005-06-21 산쿄 가부시키가이샤 신규단백질 및 그 제조방법
CA2286290A1 (en) 1997-04-15 1998-10-22 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
EP1717315A3 (en) 1997-04-16 2007-06-20 Amgen Inc. Osteoprotegerin binding proteins and receptors
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) * 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US7063960B2 (en) * 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
DK2009025T3 (da) * 1998-05-14 2011-11-14 Immunex Corp Fremgangsmåde til hæmning af osteoklast-aktivitet
CA2343654A1 (en) * 1998-09-15 2000-03-23 M&E Biotech A/S Method for down-regulating osteoprotegerin ligand activity
WO2002024896A2 (en) * 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
DE02726901T1 (de) * 2001-05-17 2004-07-15 Immunex Corp., Seattle Therapeutische verwendung von rang-antagonisten
JP2005515159A (ja) * 2001-06-06 2005-05-26 イミュネックス・コーポレーション 癌を治療するためのｒａｎｋアンタゴニストの使用
EP1409016B9 (en) * 2001-06-26 2020-10-28 Amgen Fremont Inc. Antibodies to opgl
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003086289A2 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EP3184545B1 (en) 2019-10-16
PT2305715T (pt) 2017-03-02
DK1257648T3 (da) 2008-10-27
US20030103978A1 (en) 2003-06-05
EP2105449B1 (en) 2019-07-03
PT2105449T (pt) 2019-10-18
EP2305715B1 (en) 2016-12-07
CY1122686T1 (el) 2021-03-12
JP2018064555A (ja) 2018-04-26
JP2013135670A (ja) 2013-07-11
JP5279425B2 (ja) 2013-09-04
JP2019022486A (ja) 2019-02-14
JP6453810B2 (ja) 2019-01-16
LT2105449T (lt) 2019-08-12
TWI322182B (en) 2010-03-21
JP2015131800A (ja) 2015-07-23
ES2307594T5 (es) 2017-01-30
ES2758881T3 (es) 2020-05-06
EP2105449A3 (en) 2013-03-13
ES2612124T3 (es) 2017-05-12
EP2330197A2 (en) 2011-06-08
MX363225B (es) 2019-03-15
DK1257648T4 (en) 2016-11-28
PT3184545T (pt) 2020-01-06
JP5747048B2 (ja) 2015-07-08
EP3184545A1 (en) 2017-06-28
SI2105449T1 (sl) 2019-09-30
PT1257648E (pt) 2008-09-19
ES2738798T3 (es) 2020-01-27
CY1121931T1 (el) 2020-10-14
ES2505144T3 (es) 2014-10-09
CY1108297T1 (el) 2014-02-12
JP2009060904A (ja) 2009-03-26
ATE398676T2 (de) 2008-07-15
SI2330197T1 (sl) 2015-02-27
JP2020062034A (ja) 2020-04-23
DK2330197T3 (en) 2014-12-15
HK1158696A1 (en) 2012-07-20
EP2305715A3 (en) 2012-07-25
CY1115634T1 (el) 2017-01-04
JP6647730B2 (ja) 2020-02-14
MX2019002926A (es) 2019-07-18
PT2330197E (pt) 2014-10-15
SI1257648T1 (sl) 2008-10-31
EP2305715A2 (en) 2011-04-06
EP2330197A3 (en) 2013-05-29
ES2307594T3 (es) 2008-12-01
EP2330197B1 (en) 2014-09-10
JP2016196476A (ja) 2016-11-24
DK3184545T3 (da) 2020-01-06
JP5981981B2 (ja) 2016-08-31
US20140147444A1 (en) 2014-05-29
DK2305715T3 (en) 2017-03-13
EP3613775A1 (en) 2020-02-26
EP2105449A2 (en) 2009-09-30

Similar Documents

Publication Publication Date Title
CY1118462T1 (el) Μονοκλωνικο αντισωμα κατα της πρωτεϊνης συνδεσης οστεοπροτεγερινης
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
CY1120739T1 (el) Αντισωματα αντι-il-6, συνθεσεις, μεθοδοι και χρησεις
CY1111283T1 (el) Μορια με παρατεταμενες ημι-περιοδους ζωης, συνθεσεις και χρησεις εξ αυτων
CY1119755T1 (el) Πρωτεϊνες δεσμευομενες με ανθρωπινο αντιγονο c-fms
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
BRPI0214137B8 (pt) anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo
DK1438340T3 (da) Antistoffer mod KDR, deres fremstilling og anvendelser
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
CY1113153T1 (el) ΙL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
CY1114855T1 (el) Αντισωματα και μορια που προερχονται απο αυτα που δεσμευονται στις πρωτεϊνες toy steap-1
WO2002020569A3 (en) Mammalian genes; related reagents and methods
CY1109149T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
ES2098274T3 (es) Anticuerpos monoclonales.
DE602005027399D1 (de) Für humane matriptase spezifische bindungsproteine
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
CY1114921T1 (el) Αντισωματα που δεσμευονται ανοσοειδικα στους trail υποδοχεις
BRPI0516260A (pt) antagonista de fator de necrose tumoral 1, ligante, monÈmero de anticorpo de domìnio (dab), ácido nucleico, vetor, célula hospedeira, métodos para produzir um polipeptìdeo, um monÈmero de dab, um ligante multiespecìfico, e um formato de anticorpo, e para tratar, suprimir ou prevenir uma doença, composição, uso de um antagonista, formato de anticorpo, polipeptìdeo, e, anticorpo ou fragmento de ligação de antìgeno do mesmo
CY1105580T1 (el) Νεα μορια κινασης πρωτεϊνης 14911 και χρησεις τους